颱风白鹿远离 台东富冈渔港满布杂木(3) 根据Huobi交易平台的数据     DATE: 2019-09-13 09:23

BTC最新成交价格为11487.82美元,颱风白鹿远跌幅为0.02%

根据Huobi交易平台的数据,颱风白鹿远截至07月12日上午09点,BTC最新成交价格为11487.82美元,最高价达12100美元,最低价格为11003.22美元,成交量为7.41万,跌幅为0.02%。

ETH最新成交价格为272.37美元,最高价达287.4美元,最低价格为262美元,成交量为74.46万,涨幅为1.57%。

EOS最新成交价格为4.7645美元,最高价达5.2192美元,最低价格为4.35美元,成交量为3,127.29万,涨幅为4.74%。

立即下载KNOWING新闻APP,给你移动世代的阅读体验

离台东富冈

Heat-stable carbetocin has been added to the WHO Essential Medicines List of uterotonics for the prevention of excessive bleeding after childbirth1
Excessive bleeding after birth, also known as postpartum haemorrhage (PPH), is the leading direct cause of maternal mortality worldwide2
WHO guidelines recommend heat-stable carbetocin for PPH prevention in settings where oxytocin is unavailable or its quality cannot be guaranteed, and where its cost is comparable to other effective uterotonics3*
Heat-stable carbetocin was developed by Ferring Pharmaceuticals to address limitations in refrigeration and cold-chain transport of medicines in low- and lower-middle income countries4

SAINT-PREX, Switzerland -- (BUSINESS WIRE) --

Ferring Pharmaceuticals today welcomes the World Health Organization鈥檚 (WHO) addition of heat-stable carbetocin to the WHO Model List of Essential Medicines (EML) of uterotonics for the prevention of excessive bleeding after birth.1 The EML identifies medicines the WHO deems essential for addressing the most important public health needs globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190709005661/en/

Every year, 14 million women are affected by excessive bleeding after birth, also known as postpartum haemorrhage (PPH).5 Although most deaths are preventable,6 PPH is the leading direct cause of maternal death worldwide,2 causing approximately 70,000 deaths per year,2 99% of which occur in low- and lower-middle income countries.5

鈥淭he WHO鈥檚 addition of heat-stable carbetocin to the Essential Medicines List brings us one step closer to tackling this life-threatening condition that impacts thousands of women and their families,鈥 said Klaus Dugi, Chief Medical Officer, Ferring Pharmaceuticals. 鈥淭his milestone is thanks to collaboration from stakeholders around the world, and demonstrates how work across both the public and private sectors can help achieve development goals in global health. As the manufacturer, Ferring is now seeking registrations for heat-stable carbetocin and, once approved, our priority is to make heat-stable carbetocin available at an affordable and sustainable price** in public sector healthcare facilities in low- and lower-middle income countries where cold-chain transport and refrigeration of medicines is often difficult to achieve or maintain.鈥滭/p>

This addition to the EML follows the 2018 update to the WHO鈥檚 recommendations on uterotonics for the prevention of PPH.3 The guidelines recommend heat-stable carbetocin for the prevention of excessive bleeding after all births in settings where oxytocin is unavailable or its quality cannot be guaranteed, and where its cost is comparable to other effective uterotonics.3 The CHAMPION trial, the largest clinical trial in PPH prevention, showed that heat-stable carbetocin is non-inferior to current standard of care oxytocin, for the primary outcome of 鈮?00 ml blood loss or additional uterotonic use, after vaginal birth.7 Heat-stable carbetocin remains effective at high temperatures,8 addressing a significant limitation of oxytocin, which must be stored and transported at 2 鈥 8掳C.9,10

Carbetocin is currently registered in more than 80 countries worldwide for the prevention of PPH due to uterine atony following caesarean section.11 Ferring is now seeking registrations for heat-stable carbetocin for the prevention of PPH following all births. Once approved, the heat-stable formulation of carbetocin will be available at an affordable and sustainable price** to publicly controlled or publicly funded healthcare facilities and healthcare facilities operating on a social marketing basis in low- and lower-middle income countries.

About the EML1
The WHO Model List of Essential Medicines (EML) serves as a guide for the development of national and institutional essential medicine lists and is updated and revised every two years by the WHO Expert Committee on Selection and Use of Medicines.

About the CHAMPION trial7
CHAMPION (Carbetocin Haemorrhage Prevention), the largest clinical trial in the prevention of PPH, was a double-blind, randomised, non-inferiority trial designed to compare the effectiveness and safety of investigational heat-stable carbetocin to oxytocin in the prevention of PPH after vaginal birth. The trial, funded by MSD for Mothers*** and conducted by the WHO Department of Reproductive Health and Research including the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), enrolled nearly 30,000 women in ten countries including Argentina, Egypt, India, Kenya, Nigeria, Singapore, South Africa, Thailand, Uganda and the UK. Heat-stable carbetocin is a long-acting uterotonic developed by Ferring Pharmaceuticals. The results demonstrated that heat-stable carbetocin is non-inferior to the standard of care, oxytocin, for the primary outcome of > 500 ml blood loss or additional uterotonic use. Non-inferiority was not demonstrated for the secondary primary outcome of blood loss of 1000 ml or more, however, the trial was underpowered for this outcome. There were no significant differences between groups in other measures of bleeding or in adverse effects.

* The availability of heat-stable carbetocin is subject to regulatory review and approval in relevant countries.
** This price is a subsidised price of $0.31 +/- 10% per ampoule of 100 碌g heat-stable carbetocin. This is comparable to the current United Nations Population Fund price for oxytocin of $0.33 per unit (10 I.U.).12
*** MSD for Mothers is an initiative of Merck & Co., Inc., Kenilworth, N.J., U.S.A.

About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women鈥檚 health, and in speciality areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

# # #

References

1 WHO Model List of Essential Medicines. Available at: https://apps.who.int/iris/handle/10665/325771 Last accessed: July 2019

2 Say L, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Global Health. 2014; 2(6):e323-e333. Available at: https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(14)70227-X.pdf Last accessed: July 2019

3 WHO. WHO recommendations: Uterotonics for the prevention of postpartum haemorrhage. Available at: https://apps.who.int/iris/bitstream/handle/10665/277276/9789241550420-eng.pdf?ua=1 Last accessed: July 2019

4 World Bank. World Bank Country and Lending Groups. Published 2019. Available at: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups Last accessed: July 2019

5 WHO. Priority diseases and reasons for inclusion. Postpartum haemorrhage. Available at: http://www.who.int/medicines/areas/priority_medicines/Ch6_16PPH.pdf Last accessed: July 2019.

6 WHO. Maternal mortality 鈥 Fact sheets. Published 2018. Available at: www.who.int/news-room/fact-sheets/detail/maternal-mortality Last accessed: July 2019

7 Widmer M, et al. Heat stable carbetocin vs oxytocin to prevent hemorrhage after vaginal birth. New England Journal of Medicine 2018;379:743-752

8 Malm M, et al. Development and stability of a heat-stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and middle-income countries. Journal of Peptide Science 2018;e3082

9 Widmer M, et al. Room temperature stable carbetocin for the prevention of postpartum haemorrhage during the third stage of labour in women delivering vaginally: study protocol for a randomized controlled trial. Trials 2016;17(1):143

10 Torloni MR, et al. Quality of Oxytocin Available in Low and Middle-Income Countries: A Systematic Review of the Literature (Systematic Review on Quality of Oxytocin). BJOG 2016;123(13):2076-2086

11 Ferring Pharmaceuticals. Data on file. 2019

12 UNFPA Procurement Services. Oxytocin 10 I.U./ml injection in 1ml ampoule. www.unfpaprocurement.org/products?id=OXYTOCIN_10IU/ML Last accessed: July 2019

View source version on businesswire.com: https://www.businesswire.com/news/home/20190709005661/en/

CONTACT:

Bhavin Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com

Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com

Nepal: Due to postpartum haemorrhage (PPH), Tulasi was rushed to have emergency blood transfusions after childbirth. Her husband Dinesh felt helpless, but thankfully she recovered. (Photo: Business Wire)

渔港满布杂

Heat-stable carbetocin has been added to the WHO Essential Medicines List of uterotonics for the prevention of excessive bleeding after childbirth1
Excessive bleeding after birth, also known as postpartum haemorrhage (PPH), is the leading direct cause of maternal mortality worldwide2
WHO guidelines recommend heat-stable carbetocin for PPH prevention in settings where oxytocin is unavailable or its quality cannot be guaranteed, and where its cost is comparable to other effective uterotonics3*
Heat-stable carbetocin was developed by Ferring Pharmaceuticals to address limitations in refrigeration and cold-chain transport of medicines in low- and lower-middle income countries4

SAINT-PREX, Switzerland -- (BUSINESS WIRE) --

Ferring Pharmaceuticals today welcomes the World Health Organization鈥檚 (WHO) addition of heat-stable carbetocin to the WHO Model List of Essential Medicines (EML) of uterotonics for the prevention of excessive bleeding after birth.1 The EML identifies medicines the WHO deems essential for addressing the most important public health needs globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190709005661/en/

Every year, 14 million women are affected by excessive bleeding after birth, also known as postpartum haemorrhage (PPH).5 Although most deaths are preventable,6 PPH is the leading direct cause of maternal death worldwide,2 causing approximately 70,000 deaths per year,2 99% of which occur in low- and lower-middle income countries.5

鈥淭he WHO鈥檚 addition of heat-stable carbetocin to the Essential Medicines List brings us one step closer to tackling this life-threatening condition that impacts thousands of women and their families,鈥 said Klaus Dugi, Chief Medical Officer, Ferring Pharmaceuticals. 鈥淭his milestone is thanks to collaboration from stakeholders around the world, and demonstrates how work across both the public and private sectors can help achieve development goals in global health. As the manufacturer, Ferring is now seeking registrations for heat-stable carbetocin and, once approved, our priority is to make heat-stable carbetocin available at an affordable and sustainable price** in public sector healthcare facilities in low- and lower-middle income countries where cold-chain transport and refrigeration of medicines is often difficult to achieve or maintain.鈥滭/p>

This addition to the EML follows the 2018 update to the WHO鈥檚 recommendations on uterotonics for the prevention of PPH.3 The guidelines recommend heat-stable carbetocin for the prevention of excessive bleeding after all births in settings where oxytocin is unavailable or its quality cannot be guaranteed, and where its cost is comparable to other effective uterotonics.3 The CHAMPION trial, the largest clinical trial in PPH prevention, showed that heat-stable carbetocin is non-inferior to current standard of care oxytocin, for the primary outcome of 鈮?00 ml blood loss or additional uterotonic use, after vaginal birth.7 Heat-stable carbetocin remains effective at high temperatures,8 addressing a significant limitation of oxytocin, which must be stored and transported at 2 鈥 8掳C.9,10

Carbetocin is currently registered in more than 80 countries worldwide for the prevention of PPH due to uterine atony following caesarean section.11 Ferring is now seeking registrations for heat-stable carbetocin for the prevention of PPH following all births. Once approved, the heat-stable formulation of carbetocin will be available at an affordable and sustainable price** to publicly controlled or publicly funded healthcare facilities and healthcare facilities operating on a social marketing basis in low- and lower-middle income countries.

About the EML1
The WHO Model List of Essential Medicines (EML) serves as a guide for the development of national and institutional essential medicine lists and is updated and revised every two years by the WHO Expert Committee on Selection and Use of Medicines.

About the CHAMPION trial7
CHAMPION (Carbetocin Haemorrhage Prevention), the largest clinical trial in the prevention of PPH, was a double-blind, randomised, non-inferiority trial designed to compare the effectiveness and safety of investigational heat-stable carbetocin to oxytocin in the prevention of PPH after vaginal birth. The trial, funded by MSD for Mothers*** and conducted by the WHO Department of Reproductive Health and Research including the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), enrolled nearly 30,000 women in ten countries including Argentina, Egypt, India, Kenya, Nigeria, Singapore, South Africa, Thailand, Uganda and the UK. Heat-stable carbetocin is a long-acting uterotonic developed by Ferring Pharmaceuticals. The results demonstrated that heat-stable carbetocin is non-inferior to the standard of care, oxytocin, for the primary outcome of > 500 ml blood loss or additional uterotonic use. Non-inferiority was not demonstrated for the secondary primary outcome of blood loss of 1000 ml or more, however, the trial was underpowered for this outcome. There were no significant differences between groups in other measures of bleeding or in adverse effects.

* The availability of heat-stable carbetocin is subject to regulatory review and approval in relevant countries.
** This price is a subsidised price of $0.31 +/- 10% per ampoule of 100 碌g heat-stable carbetocin. This is comparable to the current United Nations Population Fund price for oxytocin of $0.33 per unit (10 I.U.).12
*** MSD for Mothers is an initiative of Merck & Co., Inc., Kenilworth, N.J., U.S.A.

About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women鈥檚 health, and in speciality areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

# # #

References

1 WHO Model List of Essential Medicines. Available at: https://apps.who.int/iris/handle/10665/325771 Last accessed: July 2019

2 Say L, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Global Health. 2014; 2(6):e323-e333. Available at: https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(14)70227-X.pdf Last accessed: July 2019

3 WHO. WHO recommendations: Uterotonics for the prevention of postpartum haemorrhage. Available at: https://apps.who.int/iris/bitstream/handle/10665/277276/9789241550420-eng.pdf?ua=1 Last accessed: July 2019

4 World Bank. World Bank Country and Lending Groups. Published 2019. Available at: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups Last accessed: July 2019

5 WHO. Priority diseases and reasons for inclusion. Postpartum haemorrhage. Available at: http://www.who.int/medicines/areas/priority_medicines/Ch6_16PPH.pdf Last accessed: July 2019.

6 WHO. Maternal mortality 鈥 Fact sheets. Published 2018. Available at: www.who.int/news-room/fact-sheets/detail/maternal-mortality Last accessed: July 2019

7 Widmer M, et al. Heat stable carbetocin vs oxytocin to prevent hemorrhage after vaginal birth. New England Journal of Medicine 2018;379:743-752

8 Malm M, et al. Development and stability of a heat-stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and middle-income countries. Journal of Peptide Science 2018;e3082

9 Widmer M, et al. Room temperature stable carbetocin for the prevention of postpartum haemorrhage during the third stage of labour in women delivering vaginally: study protocol for a randomized controlled trial. Trials 2016;17(1):143

10 Torloni MR, et al. Quality of Oxytocin Available in Low and Middle-Income Countries: A Systematic Review of the Literature (Systematic Review on Quality of Oxytocin). BJOG 2016;123(13):2076-2086

11 Ferring Pharmaceuticals. Data on file. 2019

12 UNFPA Procurement Services. Oxytocin 10 I.U./ml injection in 1ml ampoule. www.unfpaprocurement.org/products?id=OXYTOCIN_10IU/ML Last accessed: July 2019

View source version on businesswire.com: https://www.businesswire.com/news/home/20190709005661/en/

CONTACT:

Bhavin Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com

Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com

Nepal: Due to postpartum haemorrhage (PPH), Tulasi was rushed to have emergency blood transfusions after childbirth. Her husband Dinesh felt helpless, but thankfully she recovered. (Photo: Business Wire)

颱风白鹿远离  台东富冈渔港满布杂木(3)

木3

Heat-stable carbetocin has been added to the WHO Essential Medicines List of uterotonics for the prevention of excessive bleeding after childbirth1
Excessive bleeding after birth, also known as postpartum haemorrhage (PPH), is the leading direct cause of maternal mortality worldwide2
WHO guidelines recommend heat-stable carbetocin for PPH prevention in settings where oxytocin is unavailable or its quality cannot be guaranteed, and where its cost is comparable to other effective uterotonics3*
Heat-stable carbetocin was developed by Ferring Pharmaceuticals to address limitations in refrigeration and cold-chain transport of medicines in low- and lower-middle income countries4

SAINT-PREX, Switzerland -- (BUSINESS WIRE) --

Ferring Pharmaceuticals today welcomes the World Health Organization鈥檚 (WHO) addition of heat-stable carbetocin to the WHO Model List of Essential Medicines (EML) of uterotonics for the prevention of excessive bleeding after birth.1 The EML identifies medicines the WHO deems essential for addressing the most important public health needs globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190709005661/en/

Every year, 14 million women are affected by excessive bleeding after birth, also known as postpartum haemorrhage (PPH).5 Although most deaths are preventable,6 PPH is the leading direct cause of maternal death worldwide,2 causing approximately 70,000 deaths per year,2 99% of which occur in low- and lower-middle income countries.5

鈥淭he WHO鈥檚 addition of heat-stable carbetocin to the Essential Medicines List brings us one step closer to tackling this life-threatening condition that impacts thousands of women and their families,鈥 said Klaus Dugi, Chief Medical Officer, Ferring Pharmaceuticals. 鈥淭his milestone is thanks to collaboration from stakeholders around the world, and demonstrates how work across both the public and private sectors can help achieve development goals in global health. As the manufacturer, Ferring is now seeking registrations for heat-stable carbetocin and, once approved, our priority is to make heat-stable carbetocin available at an affordable and sustainable price** in public sector healthcare facilities in low- and lower-middle income countries where cold-chain transport and refrigeration of medicines is often difficult to achieve or maintain.鈥滭/p>

This addition to the EML follows the 2018 update to the WHO鈥檚 recommendations on uterotonics for the prevention of PPH.3 The guidelines recommend heat-stable carbetocin for the prevention of excessive bleeding after all births in settings where oxytocin is unavailable or its quality cannot be guaranteed, and where its cost is comparable to other effective uterotonics.3 The CHAMPION trial, the largest clinical trial in PPH prevention, showed that heat-stable carbetocin is non-inferior to current standard of care oxytocin, for the primary outcome of 鈮?00 ml blood loss or additional uterotonic use, after vaginal birth.7 Heat-stable carbetocin remains effective at high temperatures,8 addressing a significant limitation of oxytocin, which must be stored and transported at 2 鈥 8掳C.9,10

Carbetocin is currently registered in more than 80 countries worldwide for the prevention of PPH due to uterine atony following caesarean section.11 Ferring is now seeking registrations for heat-stable carbetocin for the prevention of PPH following all births. Once approved, the heat-stable formulation of carbetocin will be available at an affordable and sustainable price** to publicly controlled or publicly funded healthcare facilities and healthcare facilities operating on a social marketing basis in low- and lower-middle income countries.

About the EML1
The WHO Model List of Essential Medicines (EML) serves as a guide for the development of national and institutional essential medicine lists and is updated and revised every two years by the WHO Expert Committee on Selection and Use of Medicines.

About the CHAMPION trial7
CHAMPION (Carbetocin Haemorrhage Prevention), the largest clinical trial in the prevention of PPH, was a double-blind, randomised, non-inferiority trial designed to compare the effectiveness and safety of investigational heat-stable carbetocin to oxytocin in the prevention of PPH after vaginal birth. The trial, funded by MSD for Mothers*** and conducted by the WHO Department of Reproductive Health and Research including the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), enrolled nearly 30,000 women in ten countries including Argentina, Egypt, India, Kenya, Nigeria, Singapore, South Africa, Thailand, Uganda and the UK. Heat-stable carbetocin is a long-acting uterotonic developed by Ferring Pharmaceuticals. The results demonstrated that heat-stable carbetocin is non-inferior to the standard of care, oxytocin, for the primary outcome of > 500 ml blood loss or additional uterotonic use. Non-inferiority was not demonstrated for the secondary primary outcome of blood loss of 1000 ml or more, however, the trial was underpowered for this outcome. There were no significant differences between groups in other measures of bleeding or in adverse effects.

* The availability of heat-stable carbetocin is subject to regulatory review and approval in relevant countries.
** This price is a subsidised price of $0.31 +/- 10% per ampoule of 100 碌g heat-stable carbetocin. This is comparable to the current United Nations Population Fund price for oxytocin of $0.33 per unit (10 I.U.).12
*** MSD for Mothers is an initiative of Merck & Co., Inc., Kenilworth, N.J., U.S.A.

About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women鈥檚 health, and in speciality areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

# # #

References

1 WHO Model List of Essential Medicines. Available at: https://apps.who.int/iris/handle/10665/325771 Last accessed: July 2019

2 Say L, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Global Health. 2014; 2(6):e323-e333. Available at: https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(14)70227-X.pdf Last accessed: July 2019

3 WHO. WHO recommendations: Uterotonics for the prevention of postpartum haemorrhage. Available at: https://apps.who.int/iris/bitstream/handle/10665/277276/9789241550420-eng.pdf?ua=1 Last accessed: July 2019

4 World Bank. World Bank Country and Lending Groups. Published 2019. Available at: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups Last accessed: July 2019

5 WHO. Priority diseases and reasons for inclusion. Postpartum haemorrhage. Available at: http://www.who.int/medicines/areas/priority_medicines/Ch6_16PPH.pdf Last accessed: July 2019.

6 WHO. Maternal mortality 鈥 Fact sheets. Published 2018. Available at: www.who.int/news-room/fact-sheets/detail/maternal-mortality Last accessed: July 2019

7 Widmer M, et al. Heat stable carbetocin vs oxytocin to prevent hemorrhage after vaginal birth. New England Journal of Medicine 2018;379:743-752

8 Malm M, et al. Development and stability of a heat-stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and middle-income countries. Journal of Peptide Science 2018;e3082

9 Widmer M, et al. Room temperature stable carbetocin for the prevention of postpartum haemorrhage during the third stage of labour in women delivering vaginally: study protocol for a randomized controlled trial. Trials 2016;17(1):143

10 Torloni MR, et al. Quality of Oxytocin Available in Low and Middle-Income Countries: A Systematic Review of the Literature (Systematic Review on Quality of Oxytocin). BJOG 2016;123(13):2076-2086

11 Ferring Pharmaceuticals. Data on file. 2019

12 UNFPA Procurement Services. Oxytocin 10 I.U./ml injection in 1ml ampoule. www.unfpaprocurement.org/products?id=OXYTOCIN_10IU/ML Last accessed: July 2019

View source version on businesswire.com: https://www.businesswire.com/news/home/20190709005661/en/

CONTACT:

Bhavin Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com

Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com

Nepal: Due to postpartum haemorrhage (PPH), Tulasi was rushed to have emergency blood transfusions after childbirth. Her husband Dinesh felt helpless, but thankfully she recovered. (Photo: Business Wire)

颱风白鹿远

Heat-stable carbetocin has been added to the WHO Essential Medicines List of uterotonics for the prevention of excessive bleeding after childbirth1
Excessive bleeding after birth, also known as postpartum haemorrhage (PPH), is the leading direct cause of maternal mortality worldwide2
WHO guidelines recommend heat-stable carbetocin for PPH prevention in settings where oxytocin is unavailable or its quality cannot be guaranteed, and where its cost is comparable to other effective uterotonics3*
Heat-stable carbetocin was developed by Ferring Pharmaceuticals to address limitations in refrigeration and cold-chain transport of medicines in low- and lower-middle income countries4

SAINT-PREX, Switzerland -- (BUSINESS WIRE) --

Ferring Pharmaceuticals today welcomes the World Health Organization鈥檚 (WHO) addition of heat-stable carbetocin to the WHO Model List of Essential Medicines (EML) of uterotonics for the prevention of excessive bleeding after birth.1 The EML identifies medicines the WHO deems essential for addressing the most important public health needs globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190709005661/en/

Every year, 14 million women are affected by excessive bleeding after birth, also known as postpartum haemorrhage (PPH).5 Although most deaths are preventable,6 PPH is the leading direct cause of maternal death worldwide,2 causing approximately 70,000 deaths per year,2 99% of which occur in low- and lower-middle income countries.5

鈥淭he WHO鈥檚 addition of heat-stable carbetocin to the Essential Medicines List brings us one step closer to tackling this life-threatening condition that impacts thousands of women and their families,鈥 said Klaus Dugi, Chief Medical Officer, Ferring Pharmaceuticals. 鈥淭his milestone is thanks to collaboration from stakeholders around the world, and demonstrates how work across both the public and private sectors can help achieve development goals in global health. As the manufacturer, Ferring is now seeking registrations for heat-stable carbetocin and, once approved, our priority is to make heat-stable carbetocin available at an affordable and sustainable price** in public sector healthcare facilities in low- and lower-middle income countries where cold-chain transport and refrigeration of medicines is often difficult to achieve or maintain.鈥滭/p>

This addition to the EML follows the 2018 update to the WHO鈥檚 recommendations on uterotonics for the prevention of PPH.3 The guidelines recommend heat-stable carbetocin for the prevention of excessive bleeding after all births in settings where oxytocin is unavailable or its quality cannot be guaranteed, and where its cost is comparable to other effective uterotonics.3 The CHAMPION trial, the largest clinical trial in PPH prevention, showed that heat-stable carbetocin is non-inferior to current standard of care oxytocin, for the primary outcome of 鈮?00 ml blood loss or additional uterotonic use, after vaginal birth.7 Heat-stable carbetocin remains effective at high temperatures,8 addressing a significant limitation of oxytocin, which must be stored and transported at 2 鈥 8掳C.9,10

Carbetocin is currently registered in more than 80 countries worldwide for the prevention of PPH due to uterine atony following caesarean section.11 Ferring is now seeking registrations for heat-stable carbetocin for the prevention of PPH following all births. Once approved, the heat-stable formulation of carbetocin will be available at an affordable and sustainable price** to publicly controlled or publicly funded healthcare facilities and healthcare facilities operating on a social marketing basis in low- and lower-middle income countries.

About the EML1
The WHO Model List of Essential Medicines (EML) serves as a guide for the development of national and institutional essential medicine lists and is updated and revised every two years by the WHO Expert Committee on Selection and Use of Medicines.

About the CHAMPION trial7
CHAMPION (Carbetocin Haemorrhage Prevention), the largest clinical trial in the prevention of PPH, was a double-blind, randomised, non-inferiority trial designed to compare the effectiveness and safety of investigational heat-stable carbetocin to oxytocin in the prevention of PPH after vaginal birth. The trial, funded by MSD for Mothers*** and conducted by the WHO Department of Reproductive Health and Research including the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), enrolled nearly 30,000 women in ten countries including Argentina, Egypt, India, Kenya, Nigeria, Singapore, South Africa, Thailand, Uganda and the UK. Heat-stable carbetocin is a long-acting uterotonic developed by Ferring Pharmaceuticals. The results demonstrated that heat-stable carbetocin is non-inferior to the standard of care, oxytocin, for the primary outcome of > 500 ml blood loss or additional uterotonic use. Non-inferiority was not demonstrated for the secondary primary outcome of blood loss of 1000 ml or more, however, the trial was underpowered for this outcome. There were no significant differences between groups in other measures of bleeding or in adverse effects.

* The availability of heat-stable carbetocin is subject to regulatory review and approval in relevant countries.
** This price is a subsidised price of $0.31 +/- 10% per ampoule of 100 碌g heat-stable carbetocin. This is comparable to the current United Nations Population Fund price for oxytocin of $0.33 per unit (10 I.U.).12
*** MSD for Mothers is an initiative of Merck & Co., Inc., Kenilworth, N.J., U.S.A.

About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women鈥檚 health, and in speciality areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

# # #

References

1 WHO Model List of Essential Medicines. Available at: https://apps.who.int/iris/handle/10665/325771 Last accessed: July 2019

2 Say L, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Global Health. 2014; 2(6):e323-e333. Available at: https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(14)70227-X.pdf Last accessed: July 2019

3 WHO. WHO recommendations: Uterotonics for the prevention of postpartum haemorrhage. Available at: https://apps.who.int/iris/bitstream/handle/10665/277276/9789241550420-eng.pdf?ua=1 Last accessed: July 2019

4 World Bank. World Bank Country and Lending Groups. Published 2019. Available at: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups Last accessed: July 2019

5 WHO. Priority diseases and reasons for inclusion. Postpartum haemorrhage. Available at: http://www.who.int/medicines/areas/priority_medicines/Ch6_16PPH.pdf Last accessed: July 2019.

6 WHO. Maternal mortality 鈥 Fact sheets. Published 2018. Available at: www.who.int/news-room/fact-sheets/detail/maternal-mortality Last accessed: July 2019

7 Widmer M, et al. Heat stable carbetocin vs oxytocin to prevent hemorrhage after vaginal birth. New England Journal of Medicine 2018;379:743-752

8 Malm M, et al. Development and stability of a heat-stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and middle-income countries. Journal of Peptide Science 2018;e3082

9 Widmer M, et al. Room temperature stable carbetocin for the prevention of postpartum haemorrhage during the third stage of labour in women delivering vaginally: study protocol for a randomized controlled trial. Trials 2016;17(1):143

10 Torloni MR, et al. Quality of Oxytocin Available in Low and Middle-Income Countries: A Systematic Review of the Literature (Systematic Review on Quality of Oxytocin). BJOG 2016;123(13):2076-2086

11 Ferring Pharmaceuticals. Data on file. 2019

12 UNFPA Procurement Services. Oxytocin 10 I.U./ml injection in 1ml ampoule. www.unfpaprocurement.org/products?id=OXYTOCIN_10IU/ML Last accessed: July 2019

View source version on businesswire.com: https://www.businesswire.com/news/home/20190709005661/en/

CONTACT:

Bhavin Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com

Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com

Nepal: Due to postpartum haemorrhage (PPH), Tulasi was rushed to have emergency blood transfusions after childbirth. Her husband Dinesh felt helpless, but thankfully she recovered. (Photo: Business Wire)

离台东富冈

Heat-stable carbetocin has been added to the WHO Essential Medicines List of uterotonics for the prevention of excessive bleeding after childbirth1
Excessive bleeding after birth, also known as postpartum haemorrhage (PPH), is the leading direct cause of maternal mortality worldwide2
WHO guidelines recommend heat-stable carbetocin for PPH prevention in settings where oxytocin is unavailable or its quality cannot be guaranteed, and where its cost is comparable to other effective uterotonics3*
Heat-stable carbetocin was developed by Ferring Pharmaceuticals to address limitations in refrigeration and cold-chain transport of medicines in low- and lower-middle income countries4

SAINT-PREX, Switzerland -- (BUSINESS WIRE) --

Ferring Pharmaceuticals today welcomes the World Health Organization鈥檚 (WHO) addition of heat-stable carbetocin to the WHO Model List of Essential Medicines (EML) of uterotonics for the prevention of excessive bleeding after birth.1 The EML identifies medicines the WHO deems essential for addressing the most important public health needs globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190709005661/en/

Every year, 14 million women are affected by excessive bleeding after birth, also known as postpartum haemorrhage (PPH).5 Although most deaths are preventable,6 PPH is the leading direct cause of maternal death worldwide,2 causing approximately 70,000 deaths per year,2 99% of which occur in low- and lower-middle income countries.5

鈥淭he WHO鈥檚 addition of heat-stable carbetocin to the Essential Medicines List brings us one step closer to tackling this life-threatening condition that impacts thousands of women and their families,鈥 said Klaus Dugi, Chief Medical Officer, Ferring Pharmaceuticals. 鈥淭his milestone is thanks to collaboration from stakeholders around the world, and demonstrates how work across both the public and private sectors can help achieve development goals in global health. As the manufacturer, Ferring is now seeking registrations for heat-stable carbetocin and, once approved, our priority is to make heat-stable carbetocin available at an affordable and sustainable price** in public sector healthcare facilities in low- and lower-middle income countries where cold-chain transport and refrigeration of medicines is often difficult to achieve or maintain.鈥滭/p>

This addition to the EML follows the 2018 update to the WHO鈥檚 recommendations on uterotonics for the prevention of PPH.3 The guidelines recommend heat-stable carbetocin for the prevention of excessive bleeding after all births in settings where oxytocin is unavailable or its quality cannot be guaranteed, and where its cost is comparable to other effective uterotonics.3 The CHAMPION trial, the largest clinical trial in PPH prevention, showed that heat-stable carbetocin is non-inferior to current standard of care oxytocin, for the primary outcome of 鈮?00 ml blood loss or additional uterotonic use, after vaginal birth.7 Heat-stable carbetocin remains effective at high temperatures,8 addressing a significant limitation of oxytocin, which must be stored and transported at 2 鈥 8掳C.9,10

Carbetocin is currently registered in more than 80 countries worldwide for the prevention of PPH due to uterine atony following caesarean section.11 Ferring is now seeking registrations for heat-stable carbetocin for the prevention of PPH following all births. Once approved, the heat-stable formulation of carbetocin will be available at an affordable and sustainable price** to publicly controlled or publicly funded healthcare facilities and healthcare facilities operating on a social marketing basis in low- and lower-middle income countries.

About the EML1
The WHO Model List of Essential Medicines (EML) serves as a guide for the development of national and institutional essential medicine lists and is updated and revised every two years by the WHO Expert Committee on Selection and Use of Medicines.

About the CHAMPION trial7
CHAMPION (Carbetocin Haemorrhage Prevention), the largest clinical trial in the prevention of PPH, was a double-blind, randomised, non-inferiority trial designed to compare the effectiveness and safety of investigational heat-stable carbetocin to oxytocin in the prevention of PPH after vaginal birth. The trial, funded by MSD for Mothers*** and conducted by the WHO Department of Reproductive Health and Research including the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), enrolled nearly 30,000 women in ten countries including Argentina, Egypt, India, Kenya, Nigeria, Singapore, South Africa, Thailand, Uganda and the UK. Heat-stable carbetocin is a long-acting uterotonic developed by Ferring Pharmaceuticals. The results demonstrated that heat-stable carbetocin is non-inferior to the standard of care, oxytocin, for the primary outcome of > 500 ml blood loss or additional uterotonic use. Non-inferiority was not demonstrated for the secondary primary outcome of blood loss of 1000 ml or more, however, the trial was underpowered for this outcome. There were no significant differences between groups in other measures of bleeding or in adverse effects.

* The availability of heat-stable carbetocin is subject to regulatory review and approval in relevant countries.
** This price is a subsidised price of $0.31 +/- 10% per ampoule of 100 碌g heat-stable carbetocin. This is comparable to the current United Nations Population Fund price for oxytocin of $0.33 per unit (10 I.U.).12
*** MSD for Mothers is an initiative of Merck & Co., Inc., Kenilworth, N.J., U.S.A.

About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women鈥檚 health, and in speciality areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

# # #

References

1 WHO Model List of Essential Medicines. Available at: https://apps.who.int/iris/handle/10665/325771 Last accessed: July 2019

2 Say L, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Global Health. 2014; 2(6):e323-e333. Available at: https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(14)70227-X.pdf Last accessed: July 2019

3 WHO. WHO recommendations: Uterotonics for the prevention of postpartum haemorrhage. Available at: https://apps.who.int/iris/bitstream/handle/10665/277276/9789241550420-eng.pdf?ua=1 Last accessed: July 2019

4 World Bank. World Bank Country and Lending Groups. Published 2019. Available at: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups Last accessed: July 2019

5 WHO. Priority diseases and reasons for inclusion. Postpartum haemorrhage. Available at: http://www.who.int/medicines/areas/priority_medicines/Ch6_16PPH.pdf Last accessed: July 2019.

6 WHO. Maternal mortality 鈥 Fact sheets. Published 2018. Available at: www.who.int/news-room/fact-sheets/detail/maternal-mortality Last accessed: July 2019

7 Widmer M, et al. Heat stable carbetocin vs oxytocin to prevent hemorrhage after vaginal birth. New England Journal of Medicine 2018;379:743-752

8 Malm M, et al. Development and stability of a heat-stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and middle-income countries. Journal of Peptide Science 2018;e3082

9 Widmer M, et al. Room temperature stable carbetocin for the prevention of postpartum haemorrhage during the third stage of labour in women delivering vaginally: study protocol for a randomized controlled trial. Trials 2016;17(1):143

10 Torloni MR, et al. Quality of Oxytocin Available in Low and Middle-Income Countries: A Systematic Review of the Literature (Systematic Review on Quality of Oxytocin). BJOG 2016;123(13):2076-2086

11 Ferring Pharmaceuticals. Data on file. 2019

12 UNFPA Procurement Services. Oxytocin 10 I.U./ml injection in 1ml ampoule. www.unfpaprocurement.org/products?id=OXYTOCIN_10IU/ML Last accessed: July 2019

View source version on businesswire.com: https://www.businesswire.com/news/home/20190709005661/en/

CONTACT:

Bhavin Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com

Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com

Nepal: Due to postpartum haemorrhage (PPH), Tulasi was rushed to have emergency blood transfusions after childbirth. Her husband Dinesh felt helpless, but thankfully she recovered. (Photo: Business Wire)

颱风白鹿远离  台东富冈渔港满布杂木(3)

渔港满布杂

Growth enabler for Surety Bonding carriers

PARIS--(BUSINESS WIRE)--Tinubu Square, a leading provider of credit insurance, surety and trade finance solutions, is launching today the Tinubu Bonding Insurance Suite (BIS), which has been developed to serve the surety bonding needs of insurers. The new product is a natural extension of Tinubu Square鈥檚 SaaS-based, end-to-end enterprise platform, used widely to help the industry manage and develop its international trade credit insurance, and now its surety bonding activities.

The new聽Tinubu BIS聽is designed to support surety carriers in their digital transformation journey and to help them to adopt the technologies they need to become more agile and enhance their value proposition to customers.

It draws on Tinubu Square鈥檚 long-standing experience delivering solutions that enable insurers to administer the lifecycle of their products from commercial and risk underwriting to claims payment. The same dedication to improving visibility and delivering results has been written into the Bonding Insurance Suite. This will give insurers optimum time to market in what is often a fast moving environment requiring innovative risk distribution strategies. The new solution will allow them to manage an increasing number of bond wordings and signature processes.

Olivier Placca, Tinubu Square Deputy CEO, said: 鈥淭inubu has grown a large and loyal customer base amongst international insurance companies. So, it has become incumbent on us to provide cutting-edge solutions that will support the industry鈥檚 business models profitably while helping insurers manage customer-focused strategies. The Bonding Insurance Suite is an extension of our existing, proven software, so it offers opportunities to digitize transactions and take advantage of data assets. It will also ensure that companies are equipped for fluctuating regulations and the particular demands of operating in multiple geographical locations. We have built our considerable knowledge and technical know-how into this new suite and this will be to the advantage of the surety bonding sector during the challenges they face in their digital transformation.鈥滭/p>

Key features聽of the Tinubu Bonding Insurance Suite include:

Administration聽鈥 The capability to manage users, their permissions and authorities within the system. Organisational changes and new staff on-boarding can be easily managed with the profile management tool. Products and their parameters can be created and administered in defined bond categories and associated to bond wordings in the bond library. The suite also includes repository of intermediaries and financial counter-parties to help manage the distribution and production network. Commercial Underwriting聽鈥 The central repository allows financial statements to be edited or uploaded in Tinubu鈥檚 proprietary pivot format and to interface with data providers. Bonding facilities and single bond submissions can be swiftly created, and users will find all the necessary information to manage their customer relationships efficiently. Risk Underwriting聽鈥 All submission, customer data and diary records are easily accessed, including past assessments and decisions. Thanks to the pdf generator, decision making support material can be created and archived. Dedicated features in the suite allow exposure at the customer level to be aggregated and construction contract execution to be monitored while analysis can be performed across portfolios thanks to Tinubu鈥檚 structured data capture of customer, obligee and intermediary information.

User Experience聽Benefits: Forms and applications can be easily imported into the application and files uploaded in a variety of format using drag and drop. Tinubu has also embedded a diary to centralise documents and archive communications at various levels. Insurers will find that they can give access to their international teams in one single solution available in English, French and Spanish.

About Tinubu Square

Founded in 2000, Tinubu Square is a software vendor, enabler of the Credit Insurance, Surety and Trade Finance digital transformation. Tinubu Square enables organizations across the world to significantly reduce their exposure to risk and their financial, operational and technical costs with best-in-class technology solutions and services. Tinubu Square provides SaaS solutions and services to different businesses including credit insurers, receivables financing organizations and multinational corporations. Tinubu Square has built an ecosystem of customers in over 20 countries worldwide and has a global presence with offices in Paris, London, New York, Montreal and Singapore. For more information:聽www.tinubu.com

Contacts

Julie Kirby 鈥 Ascendant聽
Email:聽jkirby@ascendcomms.net聽
Phone: +44 (0) 7956 955625

Tinubu Bonding Insurance Suite (Graphic: Business Wire)

木3

Growth enabler for Surety Bonding carriers

PARIS--(BUSINESS WIRE)--Tinubu Square, a leading provider of credit insurance, surety and trade finance solutions, is launching today the Tinubu Bonding Insurance Suite (BIS), which has been developed to serve the surety bonding needs of insurers. The new product is a natural extension of Tinubu Square鈥檚 SaaS-based, end-to-end enterprise platform, used widely to help the industry manage and develop its international trade credit insurance, and now its surety bonding activities.

The new聽Tinubu BIS聽is designed to support surety carriers in their digital transformation journey and to help them to adopt the technologies they need to become more agile and enhance their value proposition to customers.

It draws on Tinubu Square鈥檚 long-standing experience delivering solutions that enable insurers to administer the lifecycle of their products from commercial and risk underwriting to claims payment. The same dedication to improving visibility and delivering results has been written into the Bonding Insurance Suite. This will give insurers optimum time to market in what is often a fast moving environment requiring innovative risk distribution strategies. The new solution will allow them to manage an increasing number of bond wordings and signature processes.

Olivier Placca, Tinubu Square Deputy CEO, said: 鈥淭inubu has grown a large and loyal customer base amongst international insurance companies. So, it has become incumbent on us to provide cutting-edge solutions that will support the industry鈥檚 business models profitably while helping insurers manage customer-focused strategies. The Bonding Insurance Suite is an extension of our existing, proven software, so it offers opportunities to digitize transactions and take advantage of data assets. It will also ensure that companies are equipped for fluctuating regulations and the particular demands of operating in multiple geographical locations. We have built our considerable knowledge and technical know-how into this new suite and this will be to the advantage of the surety bonding sector during the challenges they face in their digital transformation.鈥滭/p>

Key features聽of the Tinubu Bonding Insurance Suite include:

Administration聽鈥 The capability to manage users, their permissions and authorities within the system. Organisational changes and new staff on-boarding can be easily managed with the profile management tool. Products and their parameters can be created and administered in defined bond categories and associated to bond wordings in the bond library. The suite also includes repository of intermediaries and financial counter-parties to help manage the distribution and production network. Commercial Underwriting聽鈥 The central repository allows financial statements to be edited or uploaded in Tinubu鈥檚 proprietary pivot format and to interface with data providers. Bonding facilities and single bond submissions can be swiftly created, and users will find all the necessary information to manage their customer relationships efficiently. Risk Underwriting聽鈥 All submission, customer data and diary records are easily accessed, including past assessments and decisions. Thanks to the pdf generator, decision making support material can be created and archived. Dedicated features in the suite allow exposure at the customer level to be aggregated and construction contract execution to be monitored while analysis can be performed across portfolios thanks to Tinubu鈥檚 structured data capture of customer, obligee and intermediary information.

User Experience聽Benefits: Forms and applications can be easily imported into the application and files uploaded in a variety of format using drag and drop. Tinubu has also embedded a diary to centralise documents and archive communications at various levels. Insurers will find that they can give access to their international teams in one single solution available in English, French and Spanish.

About Tinubu Square

Founded in 2000, Tinubu Square is a software vendor, enabler of the Credit Insurance, Surety and Trade Finance digital transformation. Tinubu Square enables organizations across the world to significantly reduce their exposure to risk and their financial, operational and technical costs with best-in-class technology solutions and services. Tinubu Square provides SaaS solutions and services to different businesses including credit insurers, receivables financing organizations and multinational corporations. Tinubu Square has built an ecosystem of customers in over 20 countries worldwide and has a global presence with offices in Paris, London, New York, Montreal and Singapore. For more information:聽www.tinubu.com

Contacts

Julie Kirby 鈥 Ascendant聽
Email:聽jkirby@ascendcomms.net聽
Phone: +44 (0) 7956 955625

Tinubu Bonding Insurance Suite (Graphic: Business Wire)

颱风白鹿远离  台东富冈渔港满布杂木(3)

颱风白鹿远

Growth enabler for Surety Bonding carriers

PARIS--(BUSINESS WIRE)--Tinubu Square, a leading provider of credit insurance, surety and trade finance solutions, is launching today the Tinubu Bonding Insurance Suite (BIS), which has been developed to serve the surety bonding needs of insurers. The new product is a natural extension of Tinubu Square鈥檚 SaaS-based, end-to-end enterprise platform, used widely to help the industry manage and develop its international trade credit insurance, and now its surety bonding activities.

The new聽Tinubu BIS聽is designed to support surety carriers in their digital transformation journey and to help them to adopt the technologies they need to become more agile and enhance their value proposition to customers.

It draws on Tinubu Square鈥檚 long-standing experience delivering solutions that enable insurers to administer the lifecycle of their products from commercial and risk underwriting to claims payment. The same dedication to improving visibility and delivering results has been written into the Bonding Insurance Suite. This will give insurers optimum time to market in what is often a fast moving environment requiring innovative risk distribution strategies. The new solution will allow them to manage an increasing number of bond wordings and signature processes.

Olivier Placca, Tinubu Square Deputy CEO, said: 鈥淭inubu has grown a large and loyal customer base amongst international insurance companies. So, it has become incumbent on us to provide cutting-edge solutions that will support the industry鈥檚 business models profitably while helping insurers manage customer-focused strategies. The Bonding Insurance Suite is an extension of our existing, proven software, so it offers opportunities to digitize transactions and take advantage of data assets. It will also ensure that companies are equipped for fluctuating regulations and the particular demands of operating in multiple geographical locations. We have built our considerable knowledge and technical know-how into this new suite and this will be to the advantage of the surety bonding sector during the challenges they face in their digital transformation.鈥滭/p>

Key features聽of the Tinubu Bonding Insurance Suite include:

Administration聽鈥 The capability to manage users, their permissions and authorities within the system. Organisational changes and new staff on-boarding can be easily managed with the profile management tool. Products and their parameters can be created and administered in defined bond categories and associated to bond wordings in the bond library. The suite also includes repository of intermediaries and financial counter-parties to help manage the distribution and production network. Commercial Underwriting聽鈥 The central repository allows financial statements to be edited or uploaded in Tinubu鈥檚 proprietary pivot format and to interface with data providers. Bonding facilities and single bond submissions can be swiftly created, and users will find all the necessary information to manage their customer relationships efficiently. Risk Underwriting聽鈥 All submission, customer data and diary records are easily accessed, including past assessments and decisions. Thanks to the pdf generator, decision making support material can be created and archived. Dedicated features in the suite allow exposure at the customer level to be aggregated and construction contract execution to be monitored while analysis can be performed across portfolios thanks to Tinubu鈥檚 structured data capture of customer, obligee and intermediary information.

User Experience聽Benefits: Forms and applications can be easily imported into the application and files uploaded in a variety of format using drag and drop. Tinubu has also embedded a diary to centralise documents and archive communications at various levels. Insurers will find that they can give access to their international teams in one single solution available in English, French and Spanish.

About Tinubu Square

Founded in 2000, Tinubu Square is a software vendor, enabler of the Credit Insurance, Surety and Trade Finance digital transformation. Tinubu Square enables organizations across the world to significantly reduce their exposure to risk and their financial, operational and technical costs with best-in-class technology solutions and services. Tinubu Square provides SaaS solutions and services to different businesses including credit insurers, receivables financing organizations and multinational corporations. Tinubu Square has built an ecosystem of customers in over 20 countries worldwide and has a global presence with offices in Paris, London, New York, Montreal and Singapore. For more information:聽www.tinubu.com

Contacts

Julie Kirby 鈥 Ascendant聽
Email:聽jkirby@ascendcomms.net聽
Phone: +44 (0) 7956 955625

Tinubu Bonding Insurance Suite (Graphic: Business Wire)

离台东富冈

Growth enabler for Surety Bonding carriers

PARIS--(BUSINESS WIRE)--Tinubu Square, a leading provider of credit insurance, surety and trade finance solutions, is launching today the Tinubu Bonding Insurance Suite (BIS), which has been developed to serve the surety bonding needs of insurers. The new product is a natural extension of Tinubu Square鈥檚 SaaS-based, end-to-end enterprise platform, used widely to help the industry manage and develop its international trade credit insurance, and now its surety bonding activities.

The new聽Tinubu BIS聽is designed to support surety carriers in their digital transformation journey and to help them to adopt the technologies they need to become more agile and enhance their value proposition to customers.

It draws on Tinubu Square鈥檚 long-standing experience delivering solutions that enable insurers to administer the lifecycle of their products from commercial and risk underwriting to claims payment. The same dedication to improving visibility and delivering results has been written into the Bonding Insurance Suite. This will give insurers optimum time to market in what is often a fast moving environment requiring innovative risk distribution strategies. The new solution will allow them to manage an increasing number of bond wordings and signature processes.

Olivier Placca, Tinubu Square Deputy CEO, said: 鈥淭inubu has grown a large and loyal customer base amongst international insurance companies. So, it has become incumbent on us to provide cutting-edge solutions that will support the industry鈥檚 business models profitably while helping insurers manage customer-focused strategies. The Bonding Insurance Suite is an extension of our existing, proven software, so it offers opportunities to digitize transactions and take advantage of data assets. It will also ensure that companies are equipped for fluctuating regulations and the particular demands of operating in multiple geographical locations. We have built our considerable knowledge and technical know-how into this new suite and this will be to the advantage of the surety bonding sector during the challenges they face in their digital transformation.鈥滭/p>

Key features聽of the Tinubu Bonding Insurance Suite include:

Administration聽鈥 The capability to manage users, their permissions and authorities within the system. Organisational changes and new staff on-boarding can be easily managed with the profile management tool. Products and their parameters can be created and administered in defined bond categories and associated to bond wordings in the bond library. The suite also includes repository of intermediaries and financial counter-parties to help manage the distribution and production network. Commercial Underwriting聽鈥 The central repository allows financial statements to be edited or uploaded in Tinubu鈥檚 proprietary pivot format and to interface with data providers. Bonding facilities and single bond submissions can be swiftly created, and users will find all the necessary information to manage their customer relationships efficiently. Risk Underwriting聽鈥 All submission, customer data and diary records are easily accessed, including past assessments and decisions. Thanks to the pdf generator, decision making support material can be created and archived. Dedicated features in the suite allow exposure at the customer level to be aggregated and construction contract execution to be monitored while analysis can be performed across portfolios thanks to Tinubu鈥檚 structured data capture of customer, obligee and intermediary information.

User Experience聽Benefits: Forms and applications can be easily imported into the application and files uploaded in a variety of format using drag and drop. Tinubu has also embedded a diary to centralise documents and archive communications at various levels. Insurers will find that they can give access to their international teams in one single solution available in English, French and Spanish.

About Tinubu Square

Founded in 2000, Tinubu Square is a software vendor, enabler of the Credit Insurance, Surety and Trade Finance digital transformation. Tinubu Square enables organizations across the world to significantly reduce their exposure to risk and their financial, operational and technical costs with best-in-class technology solutions and services. Tinubu Square provides SaaS solutions and services to different businesses including credit insurers, receivables financing organizations and multinational corporations. Tinubu Square has built an ecosystem of customers in over 20 countries worldwide and has a global presence with offices in Paris, London, New York, Montreal and Singapore. For more information:聽www.tinubu.com

Contacts

Julie Kirby 鈥 Ascendant聽
Email:聽jkirby@ascendcomms.net聽
Phone: +44 (0) 7956 955625

Tinubu Bonding Insurance Suite (Graphic: Business Wire)

(中央社台北16日电)台北股市今天开低狭幅震荡,渔港满布杂收 盘涨9.62点,渔港满布杂为10886.05点,涨幅0.09%,成交金额新 台币1171.33亿元。

加权指数开盘为10865点,盘中最高10899.84点, 最低10865点;不含金融股指数9144.62点,涨11.01点 。

八大类股涨跌幅:泥窑股涨1.11%、食品股跌0.31% 、塑化股跌0.34%、纺织股涨0.71%、机电股涨0.24%、 造纸股涨0.50%、营建股跌0.44%、金融股跌0.10%。

委买张数1112万5176张,委卖张数753万5911张, 成交张数442万4252张。

收盘时上涨435家,下跌369家,持平137家。

成交量前5名个股为旺宏、群创、元大沪深300正2 、联电、鸿海。

涨幅前5名个股为慧友、互亿、富鼎、清惠、荣成 。

跌幅前5名个股为耀杰-DR、本盟、乐士、瑞仪、明 辉-DR。1080716

(中央社台北16日电)双赢彩第108169期今晚开奖,木3中 奖号码为18、木315、24、23、3、22、16、19、6、12、9 、5。派彩结果,头奖摃龟。

贰奖有9注中奖,各得奖金新台币10万元。

派彩结果及中奖奖号以台彩公布为準。1080716

(中央社台北16日电)双赢彩第108169期今晚开奖,颱风白鹿远中 奖号码为18、颱风白鹿远15、24、23、3、22、16、19、6、12、9 、5。

实际中奖奖号以台彩公布为準。1080716

(中央社台北16日电)路透社报导,离台东富冈华为义大利分公司 首席执行官缪晓阳证实,离台东富冈华为在美国的研发公司将裁员 1000人。

路透社15日发自义大利米兰的报导说,缪晓阳除了 证实华为将在美国裁员的消息,并指美方下个月若仍将 华为公司纳入黑名单,华为也有「B计画」来保证零组 件的供应。

华尔街日报日前引述知情人士报导,这次裁员预计 将影响华为在美国的研发子公司Futurewei Technologies。这家子公司在德州、加州以及华盛顿州 共有约850名员工。

华为公司是中国通讯设备巨头,由于被美国政府指 为构成重大安全风险,华为期望加强在欧洲的立足点。

在证实华为在美国子公司将裁员之际,缪晓阳宣布 ,计画以3年时间在义大利投资31亿美元(约970亿台币 )。

他说,「未来3年,我们将在义大利投资19亿美元 收购供应商,12亿美元投入营运和行销,5200万美元投 入研发。」

缪晓阳表示,这个计画将直接创造1000个就业机会 ,以及2000个代工工作机会。(编辑:周慧盈/翟思嘉 )1080716

(中央社台北16日电)今彩539第108169期开奖,渔港满布杂中奖 号码9、渔港满布杂39、19、5、26。派彩结果,头奖1注中奖,奖 金新台币800万元。

贰奖169注中奖,每注奖金2万元。

3星彩中奖号码816,正彩41注中奖,每注奖金1万 2500元。

4星彩中奖号码7856,正彩8注中奖,每注奖金12万 5000元。

实际中奖奖号及派彩内容,以台彩公司公布为準。 1080716